• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13E3 filed by Fonar Corporation

    2/26/26 6:53:20 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $FONR alert in real time by email
    SC 13E3 1 d60092dsc13e3.htm SC 13E3 SC 13E3
     
     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13E-3

    RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(E)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.   )

     

     

    FONAR Corporation

    (Name of the Issuer)

     

     

    FONAR Corporation

    FONAR, LLC

    FONAR Acquisition Sub, Inc.

    Bill Benham

    Breezy Mgmt., LLC

    Brianna Damadian

    Carl Erickson

    Carol Naglieri

    Charles Green

    Cindy Hargrave

    Cynthia B. Hrubes

    Daniel Culver

    Dominick Nuzzo

    G5 Associates LLC

    Gaetano Sabatino

    George Krooss

    Gregory Heinemann

    Harold Tice

    Helen Damadian

    Hershowitz Limited Partnership

    HNA Management, LLC

    James Joseph Flanagan

    James Persoons

    Janice Veroline

    Jay Butterman

    Jevan Damadian

    John Dettori

    Jose Pizarro

    Justin Caico

    Karen Diethelm

    Kristin Randazzo

    Kurt William Reimann

    Louis Corradeno

    Luciano B. Bonanni

    Mark Decker

    Megan Flanagan

    Michael Carlin

    Mike Christie

    Peggy Anne McCann

    Richard A. Feigenbaum

    Rob Viel

    Robert Bernstein

    Robert Diamond

    Robert W. Heinemann, Jr.

    Roe Vella Brown

    Ronald G. Lehman II

    Ronald Merhige

    Ronald Wagner

    Ryan Flanagan

    RYJOKA Holdings, LLC

    Sean Flanagan

    Sid Prakash

    Sophimage LLC

    Thomas Gemma

    Timothy R. Damadian

    Tresina O’Rawe

    Vincent Orrico

    Wendy Heinemann

    Xavier Patrick Rodrigo

    (Names of Persons Filing Statement)

     

     

    Common stock, par value $0.0001 per share

    (Title of Class of Securities)

    344437 10 8

    (CUSIP Number of Class of Securities)

     

     

     

    John P. Collins

    FONAR Corporation

    110 Marcus Drive

    Melville, New York 11747

    (631) 694-2929

       

    Timothy R. Damadian

    FONAR, LLC

    265 Spagnoli Road, Suite 200

    Melville, New York 11747

    (516) 454-0700

    With copies to:

     

    Jon Venick, Esq.

    DLA Piper LLP (US)

    1251 Avenue of the Americas

    New York, NY 10020

    (212) 335-4500

     

    Denis A. Dufresne, Esq.

    Meister Seelig & Fein PLLC

    125 Park Avenue - 7th Floor

    New York, New York 10017

    (212) 655-3500

     

    Dennis C. O’Rourke, Esq.

    Moritt Hock & Hamroff LLP

    400 Garden City Plaza

    Garden City, New York 11530

    (516) 873-2000

    (Name, Address, and Telephone Numbers of Person Authorized to Receive Notices and

    Communications on Behalf of the Persons Filing Statement)

     

     

    This statement is filed in connection with (check the appropriate box):

     

    a. 

      ☒   The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934.

    b. 

      ☐   The filing of a registration statement under the Securities Act of 1933.

    c. 

      ☐   A tender offer.

    d. 

      ☐  

    None of the above.

    Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☒

    Check the following box if the filing is a final amendment reporting the results of the transaction: ☐

     

     
     


    Introduction

    This Transaction Statement on Schedule 13E-3 (as amended, this “Transaction Statement”) is being filed with the U.S. Securities and Exchange Commission (the “SEC”) pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), jointly by the following persons (each, a “Filing Person” and, collectively, the “Filing Persons”): (1) FONAR Corporation, a Delaware corporation (“FONAR” or the “Company”) and the issuer of the common stock, par value $0.0001 per share, of FONAR (the “Common Stock”), the Class B common stock, par value $0.0001 per share, of FONAR (the “Class B Common Stock”), the Class C common stock, par value $0.0001 per share, of FONAR (the “Class C Common Stock,” and collectively with the Common Stock and the Class B Common Stock, the “Company Capital Stock”), and the Class A Non-voting preferred stock, par value $0.0001 per share, of FONAR (the “Class A Non-voting Preferred Stock”), that is the subject of the Rule 13e-3 transaction for which this Transaction Statement is being filed with the SEC; (2) FONAR, LLC, a Delaware limited liability company (“Parent”); (3) FONAR Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”); and (4) each of the following:

    Bill Benham

    Breezy Mgmt., LLC

    Brianna Damadian

    Carl Erickson

    Carol Naglieri

    Charles Green

    Cindy Hargrave

    Cynthia B. Hrubes

    Daniel Culver

    Dominick Nuzzo

    G5 Associates LLC

    Gaetano Sabatino

    George Krooss

    Gregory Heinemann

    Harold Tice

    Helen Damadian

    Hershowitz Limited Partnership

    HNA Management, LLC

    James Joseph Flanagan

    James Persoons

    Janice Veroline

    Jay Butterman

    Jevan Damadian

    John Dettori

    Jose Pizarro

    Justin Caico

    Karen Diethelm

    Kristin Randazzo

    Kurt William Reimann

    Louis Corradeno

    Luciano B. Bonanni

    Mark Decker

    Megan Flanagan

    Michael Carlin

    Mike Christie

    Peggy Anne McCann

    Richard A. Feigenbaum

    Rob Viel

    Robert Bernstein

    Robert Diamond

    Robert W. Heinemann, Jr.

    Roe Vella Brown

    Ronald G. Lehman II

    Ronald Merhige

    Ronald Wagner


    Ryan Flanagan

    RYJOKA Holdings, LLC

    Sean Flanagan

    Sid Prakash

    Sophimage LLC

    Thomas Gemma

    Timothy R. Damadian

    Tresina O’Rawe

    Vincent Orrico

    Wendy Heinemann

    Xavier Patrick Rodrigo

    This Transaction Statement relates to the Agreement and Plan of Merger, dated as of December 23, 2025 (as it may be amended, supplemented or modified from time to time, the “Merger Agreement”), by and among Parent, Merger Sub and the Company. The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

    If the Merger is completed, at the effective time of the Merger, each share of Company Capital Stock and Class A Non-voting Preferred Stock that is issued and outstanding as of immediately prior to the effective time of the Merger (other than (i) shares owned by Parent, the Company or any of their respective subsidiaries, including securities held as treasury shares (collectively, “Excluded Shares”), as of the Effective Time and (ii) dissenting shares), will be converted into the right to receive cash in an amount equal to (i) $19.00 per share of each of Common Stock and Class B Common Stock, (ii) $6.34 per share of Class C Common Stock and (iii) $10.50 per share of Class A Non-voting Preferred Stock, in each instance, without interest and subject to deduction for any required withholding tax. As a result of the Merger, FONAR will cease to be a publicly traded company, the Common Stock will be delisted from the Nasdaq Stock Market LLC and deregistered under Section 12 of the Exchange Act, and FONAR will no longer file periodic reports, current reports and proxy and information statements with the SEC.

    On July 8, 2025, the FONAR Board formed a special committee comprised solely of the Company’s disinterested directors (Mr. Turk and Mr. Carrino) (the “Special Committee”), (i) to evaluate the advisability and fairness to FONAR and our stockholders (excluding the holders of Excluded Shares) of a non-binding proposal received from the Acquisition Group in July 2025, pursuant to which the Acquisition Group would potentially acquire the outstanding capital stock of the Company in a merger transaction, (ii) to examine any matters, including all information reasonably necessary to make an informed decision (including any alternative proposals or other strategic alternatives available to the Company, including maintaining the status quo as a standalone public company), in connection with such evaluation as the Special Committee deems appropriate (subject to applicable law), (iii) to engage, at the Company’s expense, such legal counsel or other advisors as the Special Committee deems appropriate in connection with the Process (as defined below), (iv) to negotiate on behalf of the Company, assess, reject, and make recommendations to the FONAR Board with respect to, with the advice of legal counsel and other advisors, the proposed merger transaction, and (v) to review and participate in the preparation and issuance of public statements and filings under applicable securities laws in connection with such a proposed transaction and related matters. The Special Committee, with the advice of outside financial and legal advisors, evaluated the Merger and negotiated the terms and conditions of the Merger Agreement, as more fully described in the Proxy Statement referred to below. At the conclusion of its review, at a meeting of the Special Committee held on December 23, 2025, the Special Committee, among other things, unanimously (1) determined that the terms of the Merger Agreement and the transactions contemplated thereby, including the Merger, are advisable, fair to and in the best interests of the Company and the holders of Company Capital Stock and Class A Non-voting Preferred Stock (excluding the holders of Excluded Shares), (2) recommended to the disinterested directors that the FONAR Board (A) adopt resolutions approving, adopting and declaring advisable the Merger Agreement and the transactions contemplated thereby, including the Merger, and (B) submit the Merger Agreement and the Merger to the Company’s stockholders for adoption and approval at a special meeting of the Company’s stockholders to consider the proposed transaction (the “Special Meeting”), and (3) recommended to the disinterested directors that the FONAR Board recommend that the Company’s stockholders vote for the adoption of the Merger Agreement and the Merger at the Special Meeting.

    The FONAR Board, following the unanimous recommendation of the Special Committee and after full disclosure of the interests in the Merger and other transactions contemplated by the Merger Agreement by the interested directors (and taking into account that directors Mr. Damadian and Mr. Lehman recused themselves and were not present for the vote, and that Ms. Maher abstained from the vote), at a meeting of the FONAR Board held on December 23, 2025 (1) determined that the Merger Agreement and the transactions contemplated thereby, including the Merger, upon the terms and subject to the conditions set forth in the Merger Agreement, are fair to, and in the best interests of, the Company and the Company’s stockholders (other than the holders of Excluded Shares); (2) approved and declared advisable the execution, delivery and performance of the Merger Agreement and the transactions contemplated thereby, including the Merger, upon the terms and subject to the conditions set forth in the Merger Agreement; (3) directed that the Merger Agreement and the Merger be submitted to a vote of the holders of Company Capital Stock for adoption at the Special Meeting in accordance with Sections 144 and 251 of the DGCL; and (4) resolved to recommend that holders of Company Capital Stock vote in favor of the adoption of the Merger Agreement in accordance with the DGCL at the Special Meeting.


    The Merger cannot be completed without (a) the affirmative vote of shares representing a majority of the Company Capital Stock outstanding and entitled to vote, voting together as a single class, after giving effect to the respective voting powers of each class of Company Capital Stock, and (b) the affirmative vote of a majority of the votes cast at the Special Meeting by disinterested stockholders of their shares of Company Capital Stock, voting together as a single class, after giving effect to the respective voting powers of each class of Company Capital Stock, as more fully described in the Proxy Statement.

    Concurrently with the filing of this Transaction Statement, the Company is filing a preliminary proxy statement (the “Proxy Statement”) under Regulation 14A of the Exchange Act with the SEC, pursuant to which the Company, on behalf of the Special Committee, is soliciting proxies from the Company’s stockholders in connection with the Merger. The Proxy Statement is attached hereto as Exhibit (a)(2)(i). A copy of the Merger Agreement is attached to the Proxy Statement as ANNEX A. Capitalized terms used but not defined in this Transaction Statement have the meanings assigned to them in the Proxy Statement.

    Pursuant to General Instruction F to Schedule 13E-3, the information in the Proxy Statement, including all annexes thereto, is expressly incorporated by reference herein in its entirety, and responses to each item herein are qualified in their entirety by the information contained in the Proxy Statement. The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the Proxy Statement of the information required to be included in response to the items of Schedule 13E-3.

    While each of the Filing Persons acknowledges that the Merger is a “going private” transaction for purposes of Rule 13e-3 under the Exchange Act, the filing of this Transaction Statement shall not be construed as an admission by any Filing Person, or by any affiliate of a Filing Person, that the Company is “controlled” by any of the Filing Persons and/or their respective affiliates.

    The information concerning the Company contained in, or incorporated by reference into, this Transaction Statement and the Proxy Statement was supplied by the Company. Similarly, all information concerning each other Filing Person contained in, or incorporated by reference into, this Transaction Statement and the Proxy Statement was supplied by such Filing Person. No Filing Person, including the Company, is responsible for the accuracy of any information supplied by any other Filing Person.


    Item 1.

    Summary Term Sheet.

    The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Questions and Answers About the Special Meeting and the Merger”

    “Summary Term Sheet”

     

    Item 2.

    Subject Company Information.

     

    (a)

    Name and address. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Important Information Regarding FONAR—Company Background”

    “The Parties to the Merger—FONAR”

     

    (b)

    Securities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Important Information Regarding FONAR—Security Ownership of Certain Beneficial Owners and Management”

    “The Special Meeting—Record Date; Shares Entitled to Vote; Quorum”

     

    (c)

    Trading market and price. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Important Information Regarding FONAR—Market Price of FONAR’s Common Stock”

     

    (d)

    Dividends. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Important Information Regarding FONAR—Dividends”

     

    (e)

    Prior public offerings. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Important Information Regarding FONAR—Prior Public Offerings”

     

    (f)

    Prior stock purchases. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Important Information Regarding FONAR—Transactions in FONAR’s Securities”

     

    Item 3.

    Identity and Background of Filing Person.

     

    (a) - (c)

    Name and address; Business and background of entities; Business and background of natural persons. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Important Information Regarding FONAR”

    “Important Information Regarding the Acquisition Group”

    “Summary Term Sheet”

    “The Parties to the Merger”

     

    Item 4.

    Terms of the Transaction.

     

    (a) (1)

    Tender Offers. Not applicable.

     

    (a) (2)

    Mergers or Similar Transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Important Information Regarding FONAR—Dividends”


    “Special Factors—Anticipated Accounting Treatment”

    “Special Factors—Background of the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Certain Material U.S. Federal Income Tax Consequences of the Merger”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Plans for FONAR after the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

    “The Merger Agreement—Conditions to the Closing”

    “The Merger Agreement—Effect of the Merger”

    “The Merger Agreement—Merger Consideration”

    “The Special Meeting—Votes Required”

    “Important Information Regarding FONAR—Past Contracts, Transactions, Negotiations and Agreements”

     

    (c)

    Different terms. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger—Voting Agreements”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “The Merger Agreement—Effect of the Merger”

     

    (d)

    Appraisal rights. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Appraisal Rights”

     

    (e)

    Provisions for unaffiliated security holders. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Provisions for Unaffiliated Stockholders”

     

    (f)

    Eligibility for listing or trading. Not applicable.

     

    Item 5.

    Past Contacts, Transactions, Negotiations and Agreements.

     

    (a)(1)-(2)

    Transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Important Information Regarding FONAR—Past Contracts, Transactions, Negotiations and Agreements”


    “Important Information Regarding FONAR—Transactions in FONAR’s Securities”

    “Special Factors—Background of the Merger”

    “Special Factors—Financing of the Merger”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger—Voting Agreements”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “The Merger Agreement”

     

    (b) - (c)

    Significant corporate events; Negotiations or contacts. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    Annex A: Merger Agreement

    “Important Information Regarding FONAR—Past Contracts, Transactions, Negotiations and Agreements”

    “Special Factors—Background of the Merger”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “Special Factors—Plans for FONAR after the Merger”

    “Special Factors—Positions of Mr. Damadian, Mr. Bonanni and Mr. Lehman as to the Fairness of the Merger”

    “Special Factors—Positions of the Acquisition Group as to the Fairness of the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

    “The Merger Agreement”

     

    (e)

    Agreements involving the subject company’s securities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Important Information Regarding FONAR—Transactions in FONAR’s Securities”

    “Special Factors—Background of the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Financing of the Merger”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “The Special Meeting—Votes Required”

    “The Merger Agreement”

     

    Item 6.

    Purposes of the Transaction and Plans or Proposals.

     

    (b)

    Use of securities acquired. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Delisting and Deregistration of FONAR’s Common Stock”

    “Special Factors—Financing of the Merger”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “Special Factors—Plans for FONAR After the Merger”

    “The Merger Agreement—Effect of the Merger”


    (c)(1)-(8)

    Plans. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    Annex A: Merger Agreement

    “Important Information Regarding FONAR—Dividends”

    “Proposal 1: The Merger Proposal”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Delisting and Deregistration of FONAR’s Common Stock”

    “Special Factors—Financing of the Merger”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “Special Factors—Plans for FONAR After the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

    “The Merger Agreement”

    “The Merger Agreement—Directors and Officers; Certificate of Incorporation; Bylaws”

    “The Merger Agreement—Effect of the Merger”

     

    Item 7.

    Purposes, Alternatives, Reasons and Effects.

     

    (a)

    Purposes. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Special Factors—Background of the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Plans for FONAR After the Merger”

    “Special Factors—Positions of Mr. Damadian, Mr. Bonanni and Mr. Lehman as to the Fairness of the Merger”

    “Special Factors—Positions of the Acquisition Group as to the Fairness of the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

     

    (b)

    Alternatives. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Special Factors—Background of the Merger”

    “Special Factors—Certain Effects on FONAR if the Merger is Not Completed”

    “Special Factors—Plans for FONAR After the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and of the Board of Directors; Fairness of the Merger”

    “Special Factors—Positions of Mr. Damadian, Mr. Bonanni and Mr. Lehman as to the Fairness of the Merger”


    “Special Factors—Positions of the Acquisition Group as to the Fairness of the Merger”

     

    (c)

    Reasons. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    Annex B: Opinion of Marshall & Stevens Transaction Advisory Services LLC

    “Special Factors—Background of the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Certain Effects on FONAR if the Merger is Not Completed”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Opinion of Marshall & Stevens”

    “Special Factors—Plans for FONAR After the Merger”

    “Special Factors—Positions of Mr. Damadian, Mr. Bonanni and Mr. Lehman as to the Fairness of the Merger”

    “Special Factors—Positions of the Acquisition Group as to the Fairness of the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

    “Special Factors—Unaudited Prospective Financial Information—December Projections”

     

    (d)

    Effects. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    Annex A: Merger Agreement

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Certain Effects on FONAR if the Merger is Not Completed”

    “Special Factors—Certain Material U.S. Federal Income Tax Consequences of the Merger”

    “Special Factors—Delisting and Deregistration of FONAR’s Common Stock”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “Special Factors—Plans for FONAR After the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

    “The Merger Agreement—Effect of the Merger”

     

    Item 8.

    Fairness of the Transaction.

     

    (a) - (b)

    Fairness; Factors considered in determining fairness. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    Annex B: Opinion of Marshall & Stevens Transaction Advisory Services LLC

    “Appraisal Rights”

    “Special Factors—Background of the Merger”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “Special Factors—Opinion of Marshall & Stevens”

    “Special Factors—Plans for FONAR After the Merger”


    “Special Factors—Positions of Mr. Damadian, Mr. Bonanni and Mr. Lehman as to the Fairness of the Merger”

    “Special Factors—Positions of the Acquisition Group as to the Fairness of the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

    “Special Factors—Summary of Discussion Materials of Marshall & Stevens”

     

    (c)

    Approval of security holders. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Proposal 1: The Merger Proposal”

    “Questions and Answers About the Special Meeting and the Merger”

    “The Merger Agreement—Conditions to the Closing”

    “The Special Meeting—Record Date; Shares Entitled to Vote; Quorum”

    “The Special Meeting—Votes Required”

     

    (d)

    Unaffiliated representative. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Special Factors—Background of the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

    “Summary Term Sheet—Introduction”

     

    (e)

    Approval of directors. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

    “Summary Term Sheet—Introduction”

     

    (f)

    Other offers. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Special Factors—Background of the Merger”

    “Special Factors—Positions of the Acquisition Group as to the Fairness of the Merger”

     

    Item 9.

    Reports, Opinions, Appraisals and Negotiations.

     

    (a)-(c)

    Report, opinion or appraisal; Preparer and summary of the report, opinion or appraisal; Availability of documents. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    Annex B: Opinion of Marshall & Stevens Transaction Advisory Services LLC

    “Special Factors—Background of the Merger”

    “Special Factors—Opinion of Marshall & Stevens”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors—Recommendation of the Special Committee”

    “Where You Can Find Additional Information”


    Item 10.

    Source and Amounts of Funds or Other Consideration.

     

    (a)-(b),(d)

    Source of funds; Conditions; Borrowed funds. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Special Factors—Financing of the Merger”

     

    (c)

    Expenses. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    Annex A: Merger Agreement

    “Special Factors—Fees and Expenses”

    “Special Factors—Plans for FONAR After the Merger”

    “The Merger Agreement—Fees and Expenses”

    “The Merger Agreement—Termination Fee”

     

    Item 11.

    Interest in Securities of the Subject Company.

     

    (a)

    Securities ownership. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Important Information Regarding FONAR—Company Background”

    “Important Information Regarding FONAR—Security Ownership of Certain Beneficial Owners and Management”

    “Important Information Regarding the Acquisition Group”

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger”

     

    (b)

    Securities transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    Annex A: Merger Agreement

    “Important Information Regarding FONAR—Transactions in FONAR’s Securities”

    “Important Information Regarding FONAR—Past Contracts, Transactions, Negotiations and Agreements”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger—Voting Agreements”

     

    Item 12.

    The Solicitation or Recommendation.

     

    (d)

    Intent to tender or vote in a going-private transaction. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Important Information Regarding FONAR—Transactions in FONAR’s Securities”

    “Important Information Regarding the Acquisition Group”

    “Questions and Answers About the Special Meeting and the Merger—Q: If a stockholder gives a proxy, how are the shares voted?”

    “Special Factors—Intent of FONAR’s Directors and Executive Officers and Certain Stockholders to Vote in Favor of the Merger”

    “Special Factors—Plans for FONAR After the Merger”

    “Special Factors—Positions of Mr. Damadian, Mr. Bonanni and Mr. Lehman as to the Fairness of the Merger”

    “Special Factors—Positions of the Acquisition Group as to the Fairness of the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”


    “The Special Meeting—Shares Held by FONAR’s Directors and Executive Officers”

     

    (e)

    Recommendation of others. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Proposal 1: The Merger Proposal”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Reasons for the Merger; Recommendation of the Special Committee and the Disinterested Directors”

    “Special Factors—Positions of Mr. Damadian, Mr. Bonanni and Mr. Lehman as to the Fairness of the Merger”

    “Special Factors—Positions of the Acquisition Group as to the Fairness of the Merger”

     

    Item 13.

    Financial Statements.

     

    (a), (c)

    Financial information; Summary information. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Important Information Regarding FONAR—Book Value Per Share”

    “Important Information Regarding FONAR—Selected Historical Consolidated Financial Data”

    “Where You Can Find Additional Information”

    In addition, the audited financial statements set forth in Part II, Item 8 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025 and the unaudited financial statements set forth in Part I, Item 1 of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025 are incorporated herein by reference.

     

    (b)

    Pro forma information. Not applicable.

     

    Item 14.

    Persons/Assets, Retained, Employed, Compensated or Used.

     

    (a)-(b)

    Solicitations or recommendations; Employees and corporate assets. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Fees and Expenses”

    “Special Factors—Positions of Mr. Damadian, Mr. Bonanni and Mr. Lehman as to the Fairness of the Merger”

    “Special Factors—Positions of the Acquisition Group as to the Fairness of the Merger”

    “The Special Meeting—Solicitation of Proxies”

     

    Item 15.

    Additional Information.

     

    (b)

    Golden parachute compensation. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Special Factors—Interests of FONAR’s Directors and Executive Officers in the Merger—Golden Parachute Compensation”

     

    (c)

    Other material information. The information set forth in the Proxy Statement, including all annexes thereto, is incorporated herein by reference.

     

    Item 16.

    Exhibits.

     

    (a)(2)(i)

    Proxy Statement of FONAR Corporation (included in Schedule 14A filed on February 26, 2026 and incorporated herein by reference).

     

    (a)(2)(ii)

    Form of Proxy Card (included in the Proxy Statement and incorporated herein by reference).

     

    (a)(2)(iii)

    Letter to Stockholders (included in the Proxy Statement and incorporated herein by reference).

     

    (a)(2)(iv)

    Notice of Special Meeting of Stockholders (included in the Proxy Statement and incorporated herein by reference).


    (a)(2)(v)

    Current Report on Form 8-K filed on December 30, 2025 (included in Schedule 14A filed on February 26, 2026 and incorporated herein by reference).

     

    (a)(2)(vi)

    Current Report on Form 8-K filed on February 17, 2026 (included in Schedule 14A filed on February 26, 2026 and incorporated herein by reference).

     

    (a)(3)(i)

    Press Release dated December 29, 2025 (included in Schedule 14A filed on February 26, 2026 and incorporated herein by reference).

     

    (b)(i)

    Commitment Letter, December 23, 2025, between OceanFirst Bank, N.A. and Parent (incorporated by reference to Exhibit 6 to Amendment No. 2 to the Schedule 13D filed by the Acquisition Group on January 2, 2026).

     

    (b)(ii)

    Form of Subordinated Secured 7% Promissory Note Subscription Agreement (incorporated by reference to Exhibit 7 to Amendment No. 2 to the Schedule 13D filed by the Acquisition Group on January 2, 2026).

     

    (c)(i)

    Opinion of Marshall & Stevens Transaction Advisory Services LLC, dated December 23, 2025 (included as Annex B to the Proxy Statement and incorporated herein by reference).

     

    (c)(ii)

    Discussion Materials of Marshall & Stevens, dated as of July 7, 2025, shared with the Special Committee on August 8, 2025.

     

    (c)(iii)

    Discussion Materials of Marshall & Stevens, dated as of November 24, 2025, shared with the Special Committee on December 2, 2025

     

    (c)(iv)

    Discussion Materials of Marshall & Stevens, dated as of December 10, 2025, shared with the Special Committee on December 23, 2025.

     

    (d)(i)

    Agreement and Plan of Merger, dated as of December 23, 2025, among FONAR Corporation, FONAR, LLC, and FONAR Acquisition Sub, Inc. (included as Annex A to the Proxy Statement and incorporated herein by reference).

     

    (d)(ii)

    Form of Voting Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 30, 2025).

     

    (d)(iii)

    Form of Class B Membership Units Subscription Agreement (incorporated by reference to Exhibit 8 to Amendment No. 2 to the Schedule 13D filed by the Acquisition Group on January 2, 2026).

     

    (f)

    Section 262 of the Delaware General Corporation Law.

     

    107

    Filing Fee Table.


    SIGNATURE

    After due inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: As of February 26, 2026

     

    FONAR Corporation
    By:  

    /s/ John P. Collins

      Name:   John P. Collins
      Title:   General Counsel
    FONAR, LLC
    By:  

    /s/ Timothy R. Damadian

      Name:   Timothy R. Damadian
      Title:   Sole Manager
    FONAR Acquisition Sub, Inc.
    By:  

    /s/ Timothy R. Damadian

      Name:   Timothy R. Damadian
      Title:   President

    /s/ Bill Benham

    Bill Benham
    Breezy Mgmt., LLC
    By:  

    /s/ Julia Eckert

      Name:   Julia Eckert
      Title:   Managing Member

    /s/ Brianna Damadian

    Brianna Damadian

    /s/ Carl Erickson

    Carl Erickson

    /s/ Carol Naglieri

    Carol Naglieri

    /s/ Charles Green

    Charles Green

    /s/ Cynthia B. Hrubes

    Cynthia B. Hrubes


    /s/ Cindy Hargrave

    Cindy Hargrave

    /s/ Daniel Culver

    Daniel Culver

    /s/ Dominick Nuzzo

    Dominick Nuzzo
    G5 Associates LLC
    By:  

    /s/ Steven Gentile

      Name:   Steven Gentile
      Title:   Member

    /s/ Gaetano Sabatino

    Gaetano Sabatino

    /s/ George Krooss

    George Krooss

    /s/ Gregory Heinemann

    Gregory Heinemann

    /s/ Harold Tice

    Harold Tice

    /s/ Helen Damadian

    Helen Damadian
    Hershowitz Limited Partnership
    By:  

    /s/ Stephen Hershowitz

      Name:   Stephen Hershowitz
      Title:   General Partner
    HNA Management, LLC
    By:  

    /s/ Nancy Persoons

      Name:   Nancy Persoons
      Title:   Managing Member

    /s/ James J. Flanagan

    James J. Flanagan


    /s/ James Persoons

    James Persoons

    /s/ Janice Veroline

    Janice Veroline

    /s/ Jay Butterman

    Jay Butterman

    /s/ Jevan Damadian

    Jevan Damadian

    /s/ John Dettori

    John Dettori

    /s/ Jose Pizarro

    Jose Pizarro

    /s/ Justin Caico

    Justin Caico

    /s/ Karen Diethelm

    Karen Diethelm

    /s/ Kristin Randazzo

    Kristin Randazzo

    /s/ Kurt W. Reimann

    Kurt W. Reimann

    /s/ Louis Corradeno

    Louis Corradeno

    /s/ Luciano B. Bonanni

    Luciano B. Bonanni

    /s/ Mark Decker

    Mark Decker

    /s/ Megan Flanagan

    Megan Flanagan

    /s/ Michael Carlin

    Michael Carlin


    /s/ Mike Christie

    Mike Christie

    /s/ Peggy Anne McCann

    Peggy Anne McCann

    /s/ Richard A. Feigenbaum

    Richard A. Feigenbaum

    /s/ Rob Viel

    Rob Viel

    /s/ Robert Bernstein

    Robert Bernstein

    /s/ Robert Diamond

    Robert Diamond

    /s/ Robert W. Heinemann, Jr.

    Robert W. Heinemann, Jr.

    /s/ Roe Vella Brown

    Roe Vella Brown

    /s/ Ronald G. Lehman II

    Ronald G. Lehman II

    /s/ Ronald Merhige

    Ronald Merhige

    /s/ Ronald Wagner

    Ronald Wagner

    /s/ Ryan Flanagan

    Ryan Flanagan

     

    RYJOKA Holdings, LLC
    By:  

    /s/ Joe Davi

      Name:   Joe Davi
      Title:   Managing Member

    /s/ Sean Flanagan

    Sean Flanagan


    /s/ Sid Prakash

    Sid Prakash
    Sophimage LLC
    By:  

    /s/ Bill O’Reilly

      Name:   Bill O’Reilly
      Title:   Managing Member

    /s/ Thomas Gemma

    Thomas Gemma

    /s/ Timothy R. Damadian

    Timothy R. Damadian

    /s/ Tresina O’Rawe

    Tresina O’Rawe

    /s/ Vincent Orrico

    Vincent Orrico

    /s/ Wendy Heinemann

    Wendy Heinemann

    /s/ Xavier P. Rodrigo

    Xavier P. Rodrigo
    Get the next $FONR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FONR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FONR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fonar Announces Financial Results for The 2nd Quarter of Fiscal 2026

    Cash and cash equivalents decreased 6% to $53.0 million at December 31, 2025, as compared to $56.3 million for the fiscal year-ended June 30, 2025.Total Revenues - Net increased by 2% to $25.5 million for the quarter ended December 31, 2025, versus the corresponding quarter one year earlier. Total Revenues - Net increased by 3% to $51.6 million for the six-month period ended December 31, 2025, versus the corresponding six-month period one year earlier.Net Income increased 15% to $2.5 million for the quarter ended December 31, 2025, versus the corresponding quarter one year earlier. Net Income decreased by 16% to $5.2 million for the six-month period ended December 31, 2025, versus the corres

    2/13/26 4:30:00 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    FONAR Signs Definitive Agreement for "Take Private" Sale to Acquisition Group Led by CEO

    FONAR stockholders to receive $19.00 per share of common stock, in an all-cash transactionMelville, New York--(Newsfile Corp. - December 29, 2025) - FONAR Corporation (NASDAQ:FONR) ("FONAR" or the "Company"), The Inventor of MR Scanning™, today confirmed that it entered into a definitive agreement on December 23, 2025 (the "Merger Agreement") with FONAR, LLC and FONAR Acquisition Sub, Inc. (collectively, "Buyer"), under which, subject to the satisfaction of the conditions set forth in the Merger Agreement, Buyer will acquire all of the issued and outstanding shares of the Company (other than shares owned by Buyer, the members of the Acquisition Group or shares held in treasury by the Company

    12/29/25 4:30:00 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fonar Announces Financial Results For The 1st Quarter of Fiscal 2026

    Cash and cash equivalents decreased 4% to $54.3 million at September 30, 2025 as compared to the fiscal year-ended June 30, 2025.Total Revenues - Net increased by 4% to $26.0 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $3.2 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Consolidated Net Income decreased 33% to $2.7 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Diluted Net Income per Common Share decreased 26% to $0.34 for the quarter ended September 30, 2025 versus the corresponding quarter one

    11/10/25 8:00:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    SEC Filings

    View All

    SEC Form SC 13E3 filed by Fonar Corporation

    SC 13E3 - FONAR CORP (0000355019) (Subject)

    2/26/26 6:53:20 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form PREM14A filed by Fonar Corporation

    PREM14A - FONAR CORP (0000355019) (Filer)

    2/25/26 9:34:57 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by Fonar Corporation

    DEFA14A - FONAR CORP (0000355019) (Filer)

    2/17/26 8:03:44 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Bonanni Luciano B bought $66,110 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $14.07), increasing direct ownership by 9% to 54,253 units

    4 - FONAR CORP (0000355019) (Issuer)

    10/3/22 6:41:44 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Damadian Timothy Raymond bought $65,205 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $13.87), increasing direct ownership by 12% to 42,700 units

    4 - FONAR CORP (0000355019) (Issuer)

    10/3/22 6:16:39 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    Financials

    Live finance-specific insights

    View All

    Fonar Announces Financial Results for The 2nd Quarter of Fiscal 2026

    Cash and cash equivalents decreased 6% to $53.0 million at December 31, 2025, as compared to $56.3 million for the fiscal year-ended June 30, 2025.Total Revenues - Net increased by 2% to $25.5 million for the quarter ended December 31, 2025, versus the corresponding quarter one year earlier. Total Revenues - Net increased by 3% to $51.6 million for the six-month period ended December 31, 2025, versus the corresponding six-month period one year earlier.Net Income increased 15% to $2.5 million for the quarter ended December 31, 2025, versus the corresponding quarter one year earlier. Net Income decreased by 16% to $5.2 million for the six-month period ended December 31, 2025, versus the corres

    2/13/26 4:30:00 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fonar Announces Financial Results For The 1st Quarter of Fiscal 2026

    Cash and cash equivalents decreased 4% to $54.3 million at September 30, 2025 as compared to the fiscal year-ended June 30, 2025.Total Revenues - Net increased by 4% to $26.0 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $3.2 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Consolidated Net Income decreased 33% to $2.7 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Diluted Net Income per Common Share decreased 26% to $0.34 for the quarter ended September 30, 2025 versus the corresponding quarter one

    11/10/25 8:00:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    FONAR Announces Financial Results for Fiscal 2025

    Cash and Cash Equivalents was $56.3 million at June 30, 2025 and the previous fiscal year. Total Revenues - Net increased 1% to $104.4 million for the fiscal year ended June 30, 2025 versus the previous fiscal year.Income from Operations decreased 30% to $11.6 million for the fiscal year ended June 30, 2025 versus the previous fiscal year. Net Income decreased 24% to $10.7 million for the fiscal year ended June 30, 2025 versus the previous fiscal year.Diluted Net Income per Common Share decreased 20% to $1.23 for the fiscal year ended June 30, 2025 versus the previous fiscal year.Working Capital increased by 4% to $127.5 million for the fiscal year ended June 30, 2025 versus the previous fis

    9/12/25 8:27:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fonar Corporation

    SC 13G - FONAR CORP (0000355019) (Subject)

    11/14/24 12:27:58 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Fonar Corporation

    SC 13G - FONAR CORP (0000355019) (Subject)

    2/13/24 5:04:39 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Fonar Corporation (Amendment)

    SC 13G/A - FONAR CORP (0000355019) (Subject)

    2/13/24 4:05:17 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $FONR
    Leadership Updates

    Live Leadership Updates

    View All

    FONAR Board of Directors Appoints Independent Director

    Melville, New York--(Newsfile Corp. - July 2, 2025) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on July 2, 2025, its board of directors appointed Mr. Robert M. Carrino as an independent director of the Company's board of directors. This appointment fills a vacancy on the board left by Ms. Claudette J.V. Chan, who recently retired from her position. The Company is very grateful for Ms. Chan's years of service and loyalty to FONAR.Timothy Damadian, chairman and CEO of FONAR, said, "Our primary source of income and growth is attributable to our diagnostic imaging management subsidiary, Health Management Company of America (HMCA). In 2009, HMCA managed 9

    7/2/25 4:10:00 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    FONAR Board of Directors Appoints Independent Director

    Melville, New York--(Newsfile Corp. - March 20, 2023) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that its board of directors appointed Jessica Maher as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, chairman, president and CEO of FONAR, said, "FONAR's primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA). As a management company, HMCA bills and collects for all services rendered at HMCA-managed and HMCA-owned facilities. These facilities, all of them located in New York and Florida and coll

    3/20/23 11:37:00 AM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fonar Board of Directors Appoints Independent Director

    Melville, New York--(Newsfile Corp. - November 23, 2021) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, president and CEO of FONAR, said, "Our primary source of income and growth is attributable to FONAR's diagnostic imaging management subsidiary, Health Management Company of America (HMCA). Mr. Collins' extensive experience in dealing with insurance companies will be very helpful to HMCA. As a management company, HMCA bills and collects for all services rendered

    11/23/21 2:07:00 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care